<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109511</url>
  </required_header>
  <id_info>
    <org_study_id>targiniqoxycodulleval</org_study_id>
    <nct_id>NCT01109511</nct_id>
  </id_info>
  <brief_title>A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
        -  To demonstrate that the treatment with OXN PR tablets up to 72 hrs after surgery is&#xD;
           superior to the treatment with OxyPR with regards to constipation in subjects with&#xD;
           postoperative pain after laparoscopic hysterectomy based on interviews 24h, 72 h and 1&#xD;
           week postoperatively.&#xD;
&#xD;
      The secondary objectives:&#xD;
&#xD;
        -  Analgesic effect (including registration during the first 24 hrs)&#xD;
&#xD;
        -  To asses the frequency of pain rescue mediation use (in the double-blind phase, 0-72&#xD;
           hrs)&#xD;
&#xD;
        -  Frequency of nausea and vomiting&#xD;
&#xD;
        -  Frequency of other adverse events&#xD;
&#xD;
        -  Appetite&#xD;
&#xD;
        -  Mobilization&#xD;
&#xD;
      The exploratory objectives:&#xD;
&#xD;
        -  Overall patient satisfaction at 24, 72 hrs and 1 week&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2010</start_date>
  <completion_date type="Actual">July 30, 2011</completion_date>
  <primary_completion_date type="Actual">June 30, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Constipation in subjects with postoperative pain</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Opioid Induced Constipation</condition>
  <arm_group>
    <arm_group_label>oxycodone+naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone alone without naloxone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naloxone</intervention_name>
    <arm_group_label>oxycodone+naloxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>oxycodone+naloxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females 18 -70 years&#xD;
&#xD;
          2. Elective, non-malignant laparoscopic gynecological surgery in general anesthesia :&#xD;
             hysterectomy/ myomectomy, ASA 1, 2 and 3&#xD;
&#xD;
          3. Subjects willing and able to participate the study and have provided informed consent&#xD;
             form -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous recent or regular opioid use (WHO step I pain treatment allowed)&#xD;
&#xD;
          2. Any situation where opioids are contraindicated.&#xD;
&#xD;
          3. Any history of moderate to severe hepatic impairment.&#xD;
&#xD;
          4. Any history of severe respiratory depression with hypoxia and/or hypercapnia&#xD;
&#xD;
          5. Any history of severe chronic obstructive pulmonary disease, cor pulmonal, acute&#xD;
             severe bronchial asthma&#xD;
&#xD;
          6. Subjects with evidence of non-opioid induced paralytic ileus&#xD;
&#xD;
          7. Subjects with evidence of severely impaired pulmonary function, myxoedema,&#xD;
             hypothyroidism&#xD;
&#xD;
          8. Subjects with evidence of Addison's disease (adrenal cortical insufficiency), toxic&#xD;
             psychosis,cholelithiasis, prostate hypertrophy, alcoholism, delirium, pancreatitis,&#xD;
             hypotension, hypertension, pre-existing cardiovascular diseases, head injury (due to&#xD;
             the risk of increased intracranial pressure), epileptic disorder or predisposition to&#xD;
             convulsions, or patients taking MAO inhibitors.&#xD;
&#xD;
          9. Any history of hypersensitivity to Oxycodone / Naloxone or to any of the excipients.&#xD;
&#xD;
         10. Active alcohol or drug abuse and/or history of opioid abuse.&#xD;
&#xD;
         11. Subjects with evidence of clinically unstable disease, as determined by medical&#xD;
             history, clinical laboratory tests, ECG results, and physical examination that, in the&#xD;
             Investigator's opinion, preclude entry into the study.&#xD;
&#xD;
         12. Subjects who have received an investigational medicinal product within 30 days of&#xD;
             study entry (defined as the start of the Screening Period).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Anesthesiology, Oslo University Hospital, Ullevaal</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Johan C RÃ¦der</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Opioid-Induced Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

